Clinical trials: Synucleinopathies
Parkinson Disease
Long-Term Vesicular Monoamine Transporter II Imaging and Clinical Assessment of Parkinson's Disease Progression
A total 40 PD subjects will be included in this study. PD subjects between 20 and 80 years of age may be eligible for this study. Candidates are screened with a medical history and physical examination, and blood test.
- Trial name
- NCT01556100
- Testing
- 18F-DTBZ AV-133
- Volunteers
- 40 people
- Sponsor
- Chang Gung Memorial Hospital
Idiopathic Parkinson's Disease
Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Parkinson's Patients
Phase 3, international, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 3-arm safety and efficacy study (Part A) with an open-label phase (Part B).
- Trial name
- TOZ-PD (NCT02453386)
- Testing
- tozadenant
- Where
- 71 sites in United States, Austria and 5 more
- Volunteers
- 449 people
- Sponsor
- Biotie Therapies Inc.
Parkinson Disease
Nilotinib in Parkinson's Disease
This study will assess the safety and tolerability of daily oral administration of nilotinib (150-300mg once daily) in Parkinson's Disease.
- Trial name
- NILO-PD (NCT03205488)
- Testing
- Cohort 1:Nilotinib Oral Capsules (150mg or 300mg), Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1)
- Where
- 24 sites in United States
- Volunteers
- 76 people
- Sponsor
- Northwestern University
Lewy Body Dementia
A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
A randomized placebo-controlled trial to evaluate the safety and efficacy of three doses of study drug LY3154207 treated for 12 weeks in participants with mild-to-moderate dementia associated with LBD (PDD or DLB).
- Trial name
- PRESENCE (NCT03305809)
- Testing
- LY3154207
- Where
- 77 sites in United States, Canada and 1 more
- Volunteers
- 344 people
- Sponsor
- Eli Lilly and Company
Parkinson Disease
Transcranial Direct Current Stimulation to Treat Symptoms of Parkinson's Disease
This study will examine the effects of transcranial direct current stimulation (tDCS) on gait (walking) problems and rigidity in patients with Parkinson's disease.
- Trial name
- NCT00082342
- Testing
- Phoressor II (IOMED)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Parkinson Disease
A Study of the Efficacy and Safety of Carbidopa-Levodopa Extended-Release Tablets in Patients With Parkinson's Disease
It is a phase II randomized, parallel, double-blind, placebo-controlled, multi-center clinical trial of the efficacy and safety of WD-1603 Carbidopa-Levodopa Extended-Release Tablets in patients with Parkinson's disease.
- Trial name
- NCT05036473
- Testing
- WD-1603 Carbidopa-Levodopa Extended-Release Tablets
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai WD Pharmaceutical Co., Ltd.
Parkinson Disease
Varenicline for Gait and Balance Impairment in Parkinson Disease
The purpose of this study is to determine if varenicline is effective in improving gait and balance impairment in patients with Parkinson disease.
- Trial name
- Chantix-PD (NCT01341080)
- Testing
- Varenicline, Sugar pill
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Rush University Medical Center